Drug Trial Radar · NCT07828860
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Sep 17, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Corvus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Safety and Efficacy of Soquelitinib in Adults with Hidradenitis Suppurativa
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
SoquelitinibDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events, changes in laboratory values, vital signs, and ECGsTime frame: up to 30 days after last intervention administration
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 9
West Lafayette, Indiana · Not yet recruiting
Clinical Site 1
Bowling Green, Kentucky · Recruiting
Clinical Site 2
Owensboro, Kentucky · Recruiting
Clinical Site 3
Boston, Massachusetts · Not yet recruiting
Clinical Site 5
New York, New York · Recruiting
Clinical Site 4
The Bronx, New York · Recruiting
Clinical Site 11
Fargo, North Dakota · Recruiting
Clinical Site 10
Mayfield Heights, Ohio · Recruiting
Clinical Site 6
Camp Hill, Pennsylvania · Recruiting
Clinical Site 8
Philadelphia, Pennsylvania · Recruiting
Clinical Site 7
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.